| Imaging, biodistribution, and dosimetry of radionuclide-labeled PD-L1 antibody in an immunocompetent mouse model of breast cancer A Josefsson, JR Nedrow, S Park, SR Banerjee, A Rittenbach, F Jammes, ... Cancer research 76 (2), 472-479, 2016 | 168 | 2016 |
| HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression N Shah, K Jin, LA Cruz, S Park, H Sadik, S Cho, CP Goswami, ... Cancer research 73 (17), 5449-5458, 2013 | 113 | 2013 |
| HOXB7 is an ERα cofactor in the activation of HER2 and multiple ER target genes leading to endocrine resistance K Jin, S Park, WW Teo, P Korangath, SS Cho, T Yoshida, B Győrffy, ... Cancer discovery 5 (9), 944-959, 2015 | 93 | 2015 |
| Imaging of programmed death ligand-1 (PD-L1): impact of protein concentration on distribution of anti-PD-L1 SPECT agent in an immunocompetent melanoma murine model. SG Nedrow JR, Josefsson A, Park S, Ranka S, Roy S J Nucl Med, 2017 | 82 | 2017 |
| HOXC10 expression supports the development of chemotherapy resistance by fine tuning DNA repair in breast cancer cells H Sadik, P Korangath, NK Nguyen, B Gyorffy, R Kumar, M Hedayati, ... Cancer research 76 (15), 4443-4456, 2016 | 73 | 2016 |
| Mirk regulates the exit of colon cancer cells from quiescence K Jin, DZ Ewton, S Park, J Hu, E Friedman Journal of biological chemistry 284 (34), 22916-22925, 2009 | 70 | 2009 |
| The survival kinase Mirk/Dyrk1B is a downstream effector of oncogenic K-ras in pancreatic cancer K Jin, S Park, DZ Ewton, E Friedman Cancer research 67 (15), 7247-7255, 2007 | 57 | 2007 |
| Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model. SG Nedrow JR, Josefsson A, Park S, Bäck T, Hobbs RF, Brayton C ... EJNMMI Res, 2017 | 43 | 2017 |
| Effective treatment of ductal carcinoma in situ with a HER-2-targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer T Yoshida, K Jin, H Song, S Park, DL Huso, Z Zhang, H Liangfeng, C Zhu, ... Oncotarget 7 (22), 33306, 2016 | 32 | 2016 |
| Inhibitors of STAT 3, β‐catenin, and IGF‐1R sensitize mouse PIK 3 CA‐mutant breast cancer to PI 3K inhibitors VF Merino, S Cho, X Liang, S Park, K Jin, Q Chen, D Pan, CA Zahnow, ... Molecular oncology 11 (5), 552-566, 2017 | 25 | 2017 |
| A conserved arginine residue in the terminal protein domain of hepatitis B virus polymerase is critical for RNA pre-genome encapsidation YC Shin, S Park, WS Ryu Journal of general virology 92 (8), 1809-1816, 2011 | 17 | 2011 |
| Human HER2 overexpressing mouse breast cancer cell lines derived from MMTV.f.HuHER2 mice: characterization and use in a model of metastatic breast cancer. SG Park S, Nedrow JR, Josefsson A Oncotarget, 2017 | 13* | 2017 |
| Small Scale Renal Dosimetry for Alpha Particle Radiopharmaceutical Therapy of Metastatic Breast Cancer With 225Ac-7.16. 4 RFH A Josefsson, C Zhu, S Park, D Abou, H Song, D Huso, T Back, F ... International Journal of Radiation Oncology• Biology• Physics 93 (3), S149-S150, 2015 | 5 | 2015 |
| Dosimetric analysis of Actinium-225 labeled anti-PD-L1 alpha particle radioimmunotherapy of melanoma cancer in an immunocompetent mouse model GS Anders Josefsson, Jessie Nedrow, Sunju Park, Sagar Ranka Journal of Nuclear Medicine 57 (supplement 2), 635-635, 2016 | 3 | 2016 |
| The survival kinase Mirk/dyrk1B is a downstream effector of oncogenic K-ras K Jin, S Park, D Ewton, E Friedman Cancer Research 67 (9_Supplement), 5246-5246, 2007 | 3 | 2007 |
| Reducing renal uptake of free 213Bi associated with the decay of 225Ac-labeled radiopharmaceuticals J NEDROW, A JOSEFSSON, S PARK, RF HOBBS, F BRUCHERTSEIFER, ... | 2 | 2017 |
| Combining α-particle radiopharmaceutical therapy using Actinium-225 and immunotherapy with anti-PD-L1 antibodies in a murine immunocompetent metastatic bre... GS Anders Josefsson, Jessie R Nedrow, Sunju Park, Sagar Ranka Cancer Research 76 (14 Supplement), 3052-3052, 2016 | 2 | 2016 |
| Actinium-225 Labeled Antibody Therapy Micro-Scale Dosimetry in a Murine Model and Predicted Dosimetric Impact for Human Clinical Use A Josefsson, J Nedrow, S Park, F Bruchertseifer, A Morgenstern, ... MEDICAL PHYSICS 44 (6), 2982-2982, 2017 | | 2017 |
| Abstract LB-183: The impact of protein concentration on the distribution of 111In-antibody conjugate for imaging of programmed death-ligand 1 (PD-L1) J Nedrow, A Josefsson, S Park, S Ranka, G Sgouros Cancer Research 76 (14_Supplement), LB-183-LB-183, 2016 | | 2016 |
| Anti-PD-L1 antibody biodistribution, imaging and dosimetry in a pre-clinical breast cancer model: prospects for combination immune checkpoint inhibition and radiopharmaceutical … A Josefsson, S Park, F Jammes, S Ray, G Sgouros Journal of Nuclear Medicine 56 (supplement 3), 282-282, 2015 | | 2015 |
George SgourosProfessor of Radiology and Radiation Sciences, Johns Hopkins UniversityVerified email at jhmi.edu
